{"id":"W4207018755","doi":"10.1016/j.euros.2021.12.007","title":"Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis","year":2022,"lang":"en","type":"review","venue":"European Urology Open Science","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sinai Health System; Public Health Ontario; University of Toronto; Lunenfeld-Tanenbaum Research Institute; University of Calgary","funders":"","keywords":"Medicine; Axitinib; Oncology; Internal medicine; Ipilimumab; Nivolumab; Discontinuation; Population; Cabozantinib; Clinical endpoint; Pembrolizumab; Renal cell carcinoma; Adverse effect; Progression-free survival; Randomized controlled trial; Clinical trial; Meta-analysis; Immunotherapy; Cancer; Chemotherapy; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01115232,0.0006712776,0.01075548,0.000453461,0.0004212105,0.00008215298,0.001606855,0.00005019354,0.0001892675],"category_scores_gemma":[0.0005528799,0.0003980696,0.001354633,0.002155706,0.0006123156,0.0001042582,0.00122014,0.000344734,0.000009682252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001168011,"about_ca_system_score_gemma":0.0003869062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001922987,"about_ca_topic_score_gemma":0.000003653593,"domain_scores_codex":[0.9924065,0.002956956,0.002105441,0.00145526,0.0005497304,0.000526091],"domain_scores_gemma":[0.993923,0.001987129,0.001935276,0.001678288,0.0001827892,0.000293487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0002112946,0.0002474918,0.00001757457,0.9513981,0.04370307,0.0003149618,0.0001533467,0.00005719541,0.000001622467,0.00006097386,0.000155476,0.003678922],"study_design_scores_gemma":[0.001683136,0.002113835,0.00004976582,0.009206535,0.9358808,0.001430839,0.00001166111,0.00004286358,7.726114e-7,0.000003915568,0.04918883,0.0003870434],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005305184,0.9833027,0.000140006,0.0001147452,0.00004760126,0.01521992,0.00009907899,0.00001495461,0.001007921],"genre_scores_gemma":[0.005044619,0.9919526,0.0008272899,0.000443136,0.00002598623,0.0009399695,0.0001043757,0.00007204537,0.0005899515],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9421915,"threshold_uncertainty_score":0.9998471,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1654302413443574,"score_gpt":0.3639401654332167,"score_spread":0.1985099240888592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}